Format

Send to

Choose Destination
Int Urogynecol J. 2012 Oct;23(10):1373-8. Epub 2012 Apr 25.

Two-year follow-up of an open-label multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and stress-predominant mixed incontinence.

Author information

1
Department of Urogynaecology, Birmingham Women's Hospital, Methchley Lane, Edgbaston, Birmingham B15 2TG, UK.

Abstract

INTRODUCTION AND HYPOTHESIS:

Polyacrylamide hydrogel (PAHG, Bulkamid®) is a promising urethral bulking agent. This article presents the 2-year follow-up results of a multicenter study of PAHG injections for treating stress and stress-predominant mixed urinary incontinence.

METHODS:

Submucosal injection of PAHG was performed in 135 women with urinary incontinence, with subjective and objective assessment of the efficacy and safety 24 months postinjection.

RESULTS:

At 24 months, the subjective responder rate was 64 % (a statistically non-significant reduction from 67 % at 12 months). The decreased number of incontinence episodes and urine leakage were maintained compared with the result from the 12-month evaluations, as were objective result rates and quality of life data. No safety issues occurred.

CONCLUSIONS:

PAHG is an effective and safe treatment option for women with stress-predominant mixed urinary incontinence, with maintained medium-term responder rates.

PMID:
22531952
PMCID:
PMC3448051
DOI:
10.1007/s00192-012-1761-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center